Stocks
Spero Secures Cash Runway to H2 2029 with $105M Financing
Spero Therapeutics has extended its cash runway into the second half of 2029 following a $105 million nondilutive royalty financing. This move,...
#biotechnology 17 articles
Stocks
Atea Projects Over $700M Annual U.S. HCV Revenue Potential
Atea Pharmaceuticals (AVIR) outlined peak annual U.S. net revenue potential exceeding $700 million, driven by its mid-2028 hepatitis C (HCV) launch. This...
Stocks
Vaxart Targets H1 2027 for Phase IIb COVID-19 Data, Backed by BARDA
Vaxart (VXRT) announced plans to release top-line data from its Phase IIb COVID-19 trial in the first half of 2027, supported by...
Stocks
Summit Therapeutics Sets November 14 FDA PDUFA Date for Ivonescimab
Summit Therapeutics has received a November 14 PDUFA date for its ivonescimab BLA. The company is also planning the HARMONi-3 PFS trial...
Stocks
HHS, VA Memorandum Boosts Psychedelic Drugmakers
A new memorandum of understanding between HHS and the VA could significantly benefit companies developing psychedelic-based drug treatments for veterans.
Stocks
Definium Therapeutics Prices $700M Public Offering
Definium Therapeutics announced the pricing of an upsized public offering, raising approximately $700 million in gross proceeds.
Stocks
Biogen Acquires RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...
Stocks
Incyte’s Monjuvi Lifts Lymphoma Survival 25% in Late-Stage Trial
Incyte's immunotherapy Monjuvi, developed with Xencor, demonstrated a 25% improvement in cancer-free survival in a late-stage trial for a common lymphoma type,...
Stocks
NervGen Pharma Prices $60 Million Public Offering
NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.